HPQ reports fiscal Q3 results on August 26 carrying a 20% one-month rally into a print where Wall Street's consensus target sits well below the current price — a gap that makes the earnings release more about defending recent gains than building on them.
The most striking tension heading into the print is the divergence between where the stock trades and where analysts think it belongs. The consensus mean target is $23.10, roughly 22% below HPQ's current price of $29.71. Goldman Sachs reiterated its Sell rating on August 12, lifting its target only to $21 — still implying deep downside. Targets from JPMorgan, UBS, Barclays, Morgan Stanley, and B of A range from $18 to $26, with every major firm holding either a Sell, Underweight, Underperform, or Neutral rating. The Street raised targets after the May print — when the stock jumped 17% in a single session on strong results — but the subsequent 20% run in August has now dragged HPQ well through even the most optimistic of those revised levels. Bulls point to a deeply discounted valuation, with the P/E near 10x and EV/EBITDA around 7.7x, plus a value factor score that ranks in the top tier of the hardware universe. Bears counter that the EPS momentum ranking sits in just the 18th percentile on a 30-day basis and the 32nd on 90 days, meaning estimate revisions are not corroborating the price action.
Options positioning has shifted more defensive as the stock has climbed. The put/call ratio has risen to 1.37, above its 20-day average of 1.21, pointing to increased demand for downside protection. That drift toward puts has been consistent over the past two weeks — the PCR was below 0.90 in late July and has moved steadily higher as the stock appreciated. At the same time, the borrow market tells a calmer story. Availability is loose at 363%, well within normal ranges, and cost to borrow has eased to 0.41%, down roughly 16% on the month. Short interest itself has dropped sharply — falling about 25% in a month to 7.4% of the float, as short sellers covered into the rally. The ORTEX short score has also retreated from 58.6 on August 10 to 52.9, reflecting the reduction in positioning pressure.
Insider activity adds a note of caution. The CFO sold nearly $2 million worth of shares on August 5, and the Chief Commercial Officer has sold in multiple tranches across July and August at prices between $28 and $30 — right where the stock trades now. These are not large enough to suggest distress, but the pattern of executives trimming at current levels is a data point worth noting alongside the analyst skepticism.
The August 26 print is therefore less about whether HP Inc. can beat estimates and more about whether the underlying business momentum justifies a stock that has run 20% in a month to trade 29% above the average analyst target.
See the live data behind this article on ORTEX.
Open HPQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
